According to studies in AD mouse models based on APP and PS1 mutations, both Ca2+ hyperactivity and hypoactivity have been described at the neuronal level, with hyperactivity dominating the early stage of the disease, being brought by soluble Aβ10–13. This evidence concerns the gene PSEN1 and Alzheimer disease.